A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

January 10, 2019

Study Completion Date

June 10, 2019

Conditions
Pancreatic Ductal AdenocarcinomaPancreatic Cancer
Interventions
DRUG

PEGylated Recombinant Human Hyaluronidase (PEGPH20)

PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.

DRUG

Avelumab

Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.

Trial Locations (3)

28046

Hospital Universitario La Paz, Madrid

Unknown

Hospital Universitario Fuenlabrada, Fuenlabrada

Hospital Ramon y Cajal, Madrid

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PH Research, S.L.

OTHER